Renewal of European EMA EPAR and Solidification of Uzpruvo's Regulatory Status

The European Medicines Agency (EMA) has renewed the European Public Assessment Report (EPAR) for 'Uzpruvo (development name AVT04)', a ustekinumab biosimilar from Alvotech and STADA Arzneimittel, reaffirming the product's official regulatory status. This renewal signifies that post-marketing pharmacovigilance and manufacturing quality compliance are being met without issues following the European Commission (EC) marketing authorization in January 2024. It demonstrates that the pan-European commercial launch, which took place in July 2024 immediately following the expiration of the Supplementary Protection Certificate (SPC) for Johnson & Johnson’s (JNJ) original drug 'Stelara', is proceeding smoothly without regulatory disruption.

Scientific Basis for Phase 3 Equivalence Verification and Switching

Uzpruvo has firmly established therapeutic equivalence to the reference product in a large-scale global randomized Phase 3 clinical trial (AVT04-GL-301) involving patients with moderate to severe plaque psoriasis. At week 12 of treatment, the Uzpruvo group achieved a Psoriasis Area and Severity Index (PASI) improvement rate of 87.3%, compared to 86.8% for the Stelara control group, clearly meeting the predefined equivalence margin (90% confidence interval -2.14% to 3.01%). Furthermore, through switching analysis included in the clinical design, decisive clinical data was secured showing that patients previously treated with Stelara face no loss of efficacy or increased risk of immunogenicity when transitioning to Uzpruvo.

First-Mover Advantage in the €2.5 Billion European Autoimmune Market

The ustekinumab market in Europe is valued at approximately €2.5 billion (about $2.7 billion) annually, and Uzpruvo’s commercial value is extremely high as the first approved drug to break the original product’s monopoly on the interleukin-12/23 (IL-12/23) target. It targets the demand for healthcare system cost savings by covering major indications such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As powerful competing biosimilars such as Celltrion's 'Steqeyma', Samsung Bioepis' 'Pyzchiva', and Amgen's 'Wezlana' enter the market, this serves as a key opportunity to solidify its first-mover advantage.

Alvotech's Manufacturing Efficiency and STADA's Local Sales Synergy

The exclusive commercialization partnership model between Alvotech, an Icelandic biosimilar developer, and STADA, a German pharmaceutical giant, has proven its operational stability through this regulatory report renewal. The stable drug substance supply chain produced at Alvotech's state-of-the-art biomanufacturing facilities, combined with STADA's specialized distribution network established in over 30 European countries, is maximizing market penetration. In the increasingly competitive European tender environment, they are rapidly expanding prescription market share by providing supplies at a significant discount compared to the original drug's price, based on cost competitiveness.